Analyst Price Targets — SYRE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 27, 2026 6:20 am | Yatin Suneja | Guggenheim | $130.00 | $93.61 | StreetInsider | Guggenheim Reiterates Buy Rating on Spyre (SYRE) |
| August 26, 2026 11:59 am | — | Wedbush | $123.00 | $95.18 | TheFly | Spyre Therapeutics price target lowered to $123 from $130 at Wedbush |
| August 26, 2026 11:34 am | — | BTIG | $121.00 | $107.36 | TheFly | Spyre Therapeutics price target lowered to $121 from $132 at BTIG |
| August 26, 2026 8:36 am | — | Deutsche Bank | $127.00 | $107.36 | TheFly | Spyre Therapeutics price target lowered to $127 from $135 at Deutsche Bank |
| August 5, 2026 12:00 pm | David Nierengarten | Wedbush | $130.00 | $105.83 | TheFly | Spyre Therapeutics price target raised to $130 from $100 at Wedbush |
| August 5, 2026 11:34 am | — | Robert W. Baird | $120.00 | $104.94 | TheFly | Spyre Therapeutics price target raised to $120 from $90 at Baird |
| August 5, 2026 10:53 am | — | Wells Fargo | $115.00 | $104.94 | TheFly | Spyre Therapeutics price target raised to $115 from $90 at Wells Fargo |
| July 13, 2026 10:44 am | Joseph Catanzaro | Mizuho Securities | $120.00 | $97.74 | StreetInsider | Spyre (SYRE) PT Raised to $120 at Mizuho |
| June 23, 2026 12:47 pm | — | Deutsche Bank | $135.00 | $101.42 | TheFly | Spyre Therapeutics price target raised to $135 from $115 at Deutsche Bank |
| June 16, 2026 1:18 pm | — | Wedbush | $100.00 | $82.07 | TheFly | Spyre Therapeutics price target raised to $100 from $80 at Wedbush |
Latest News for SYRE
Spyre's SPY072 shows activity in RA, but a smaller-than-expected benefit shifts its focus toward broader autoimmune uses and combinations.
Spyre Therapeutics, Inc. (NASDAQ:SYRE) stock is trading lower on Wednesday after the company shared topline findings from the rheumatoid arthritis (RA) segment of its Phase 2 SKYWAY trial for SPY072.
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50)
SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.
Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SYRE.
U.S. House Trading
No House trades found for SYRE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.